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Leonard (Len) I. Zon was born in Hartford, CT, USA. He received
his undergraduate degree in Chemistry and Natural Sciences from
Muhlenberg College in Allentown, PA and, in 1983, obtained an
M.D. degree from Jefferson Medical College in neighboring city
Philadelphia. While undertaking clinical training at Deaconess
Medical Center, he was appointed a fellow in medical oncology at
Dana-Farber Cancer Institute. As a post-doctoral research associate
in Stuart Orkin’s lab, Len sought to understand how specific blood
lineages are programmed at the molecular level. During this time,
he cloned GATA-1, which encodes a transcription factor that is
essential for hematopoiesis. Despite having made significant
breakthroughs in HIV research as part of his clinical training, this
finding inspired Len to continue working at the bench to
investigate blood cell development using animal models. This
decision ultimately led to his introduction to zebrafish as a model
for vertebrate development and disease, and, although he began as
an outsider to the field, he has since established himself a leading
figure in the zebrafish world. The Zon laboratory was one of the
first to demonstrate the translational potential of the model, and
Len has become an advocate for adopting zebrafish in drug
discovery pipelines. As well as his notable successes in
understanding and treating cancer, he is widely renowned for his
work in stem cell biology. Len is currently the Grousbeck
Professor of Pediatric Medicine at Harvard Medical School,
Investigator at Howard Hughes Medical Institute, and Director of
the Stem Cell Program at the Children’s Hospital Boston. He is
founder of the International Society of Stem Cell Research
(ISSCR), and recently co-founded the Zebrafish Disease Models
Society. 
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Let’s start with your background. Why did you end up
becoming a physician and also a scientist?
The evolution of my career started while I was in college. I was
doing research just to try it out but I didn’t really think that it was
going to be for me – I really wanted to be a clinician. I decided I
wanted to be a community pediatrician and put up a shingle and take
care of patients. So, I applied for medical school [Jefferson Medical
College]. At Jefferson, I went to a lecture by a famous hematologist,
Allan Erslev. He had discovered a hormone called erythropoietin
that stimulated the red blood cells to divide. I was so impressed that
a hormone could control blood cell development that I asked if I
could work in his laboratory during the summer. Once I was in his
lab I started perfusing rat livers in search of erythropoietin and it’s
then that I decided this was the career for me. Allan advised me to
go to Boston to become an academic hematologist, and so I ended
up doing my clinical training at Harvard. Around the same time the
AIDS epidemic was in full swing, and I started looking with interest
at blood counts of AIDS patients. I was one of the first people to
note that individuals with AIDS are anemic and have a low platelet
count. This discovery resulted in a Nature paper, and I became even
more hooked on research.
Soon afterwards, I was appointed as fellow at the Dana-Farber
Cancer Institute. I think most people expected that I would end up
as a clinician, but I felt that I needed to immerse myself in basic
research. I had always wanted to go to Stuart Orkin’s lab, and
luckily I was able to get a post-doc position in his group. This move
started me on the track to becoming a research scientist. It turned
out I was good at basic science research and I really enjoyed it and
got great mentorship in Stuart’s lab. 
It’s interesting that you have worn the two hats of ‘clinician’
and ‘basic scientist’ since the early days. Which people
influenced you the most at the start of your career?
The first person was Allan Erslev, who I’ve already mentioned.
There was also an assistant professor at the time, Jaime Caro, 
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who really mentored me in my first lab experience. Allan has
unfortunately passed away, but I still talk to Jaime about things. 
I think you couldn’t pick a better mentor than Stuart [Orkin]. He is
also a physician as well as a scientist, and he applies an extreme rigor
to his science – it is always high quality. He shoots for the stars but
always maintains this incredible rigor in his work, which has taught
me a lot about how to do science. I’ve been lucky enough to have the
office next door to him for 20 years and it’s been wonderful. 
I have a few other mentors, including Sam [Samuel] Lux, who is
a specialist in hematology. He is the person who discovered ankyrin
over in Harvey Lodish’s lab. Sam is an excellent scientist, a very
smart person, and wonderful to talk to and approach for advice.
There’s also David Nathan, who is the kingpin of hematology – he
was chairman of pediatrics, chairman of hematology and is also the
president of Dana-Farber. He has given me a lot of great advice over
the years. Lastly, one of my mentors was Jerry [Jerome] Groopman,
who is a HIV researcher. I worked with him during my medical
residency, looking at the blood manifestations of AIDS. He now
writes a lot in The New York Times and has written books on patient
care. 
“At the top of my list of messages to
pass on to trainees is how to be a good
scientist. I think a big part of this is
being able to take risks”
What did you learn from these mentors in terms of ways to
run a lab? Some excellent scientists have come out of your
group – what’s your style of training them? 
I have a very big group, currently with 19 post-docs and ten students.
It is probably one of the larger laboratories in the institute. I try to treat
people the way I would want to be treated and pass on advice that I
think will be the most useful. At the top of my list of messages to pass
on to trainees is how to be a good scientist. I think a big part of this is
being able to take risks. When starting out, a lot of people like to do
a safe project that is likely to finish in 2 years, and this may suffice
for a short period of time, but later on when you’re trying to get your
own lab going, you need to have breadth and to take risks. I try to help
students and post-docs to have a balanced portfolio, so most members
of my lab have two projects: a 75% project that aims to change the
world and a 25% project that is almost guaranteed to work.
Doing the science right is the top priority, but, for running a lab,
interpersonal skills are also important. Early career researchers aren’t
given much formal training on how to run a lab and how to treat
people. There is a mentoring system in place for my graduate students
– I meet with them every other week and make sure I’m imparting
advice on how to do science. I also have regular meetings with post-
docs and, over the past 3 years or so, I’ve been coordinating talks
where I cover topics that are not scientific but give tips on how to run
a lab; for example, how to manage a budget, and how to market
yourself. These are things I think scientists need to know. As a PI, you
can’t meet everyone’s needs in a lab, although you hope that you do.
Some people end up doing really well and some people sadly don’t,
but you just do the best you can as a mentor.
“Doing the science right is the top
priority, but, for running a lab,
interpersonal skills are also important”
Moving back to your research – how did you get involved
with zebrafish? It’s quite a leap for someone who was used
to seeing patients.
To tell this story I need to go back to the point where I had just cloned
the gene encoding a transcription factor called GATA-1 in Stuart’s lab.
This is the master regulator of the red blood cell lineage. The
interesting thing about GATA-1 is that stem cells don’t really express
it – it’s red-blood-cell-specific. As I started to set up my own lab, I
wanted to figure out how the transcription factor was being turned on.
I knew I didn’t want to just define the regulatory elements in the
GATA-1 promoter and so I started to think about it as a developmental
problem. How does an embryo turn this gene, and thereby blood
development, on? I decided to use mouse genetics to get some
answers. So, I went over to see a friend at MIT to get help on
dissecting out 7.5-day-old mouse embryos – this is when the yolk-sac
blood island originates. After 6 hours, I had only six embryos in a
dish, and I knew that the low number of embryos would make
everything I thought I could do impossible. It was very frustrating. 
When I returned to my lab, a friend of mine called Celeste Simon
who is now a Professor at Penn [University of Pennsylvania]
happened to be there, and she said I looked terrible. I told her what
had happened, and she invited me to a party at her house. It was at
this party that I first came across Gerald Thomsen, who is now at
Stonybrook, and I shared my story about dissecting mouse embryos
with him. He said I needed an externally fertilized animal like
Xenopus. An externally fertilized embryo can be easily observed, and
eventually blood formation can be visualized. Gerry was working in
Douglas Melton’s lab at the time, and he suggested that I go over and
have a chat with Doug about using frogs to study hematopoiesis. With
Doug’s help, things started to take off and after 2-3 years we were able
to inject a homeobox gene into a frog embryo and turn the entire
embryo into a blood island. This was very exciting, but I still wasn’t
sure I wanted to stay in the frog system – it’s difficult to do genetics
in frogs, and I always valued genetics.
Around that time, I presented the frog work at a hemoglobin-
switching meeting off the coast of Seattle. Frank Grosveld [now at
Erasmus MC], who works on transgenic mice, was there and he
wanted to talk to me about my presentation. He said he loved what
we’d done with frogs, but felt it wasn’t the right system to do
genetics, and he pointed me towards zebrafish. He made a big point
that if you immerse yourself in a field early on then you will really
reap the benefits later on, as he had done with transgenic mice.
Anyway, I thought about it, and the next day I was contacted by an
investigator named William Dietrich, who is at Northeastern
University. Bill works on the Antarctic icefish. These fish have lost
the expression of globins during evolution, as an adaptation to their
environment in Antarctica. Bill was interested in coming to my lab
on sabbatical to study the effect of cold adaptation on the
transcription of globin genes. I said I didn’t want to work on
Antarctic fish but asked if he was interested in working on blood
development in zebrafish – and he was. We got hold of a zebrafish
mutant with no blood from Walter Gilbert’s lab and, within a week,
people were saying to me: “you’re going to be a zebrafish
researcher”. And that’s what happened. 
You started as an outsider but quickly became an insider in
the zebrafish field. How have you seen the field change? 
The field was kind of set up by an amazing group in Oregon who
focused on the neurobiology of fish. Other groups started to
establish screens to look for mutants that would affect organ
development. Then there was an influx of people, including me,
who were interested in disease. By the end of the last century there
















were a fair number of investigators all working on screening mutant
fish to understand organ development, with most of the work being
done on embryos. It was an exciting time and we learned a lot.
The technology took off after the year 2000. Morpholinos were
developed and we could finally do genetics, and use it to find out
which pathways affect which organs. In my lab, we were looking
for mutations that decrease blood cell levels, and four times we
identified a mutant where the gene hadn’t previously been
characterized. Then we found humans who carried mutations in
those genes, so effectively discovered four novel human diseases as
a result of research in fish. 
What I’ve really seen burst onto the scene is transgenics. At a
certain time I remember trying to convince my lab to create a
transgenic zebrafish mutant and I couldn’t get anybody in the lab to
do it. Then Shuo Lin published a paper showing the Gata-1
promoter driving GFP and showed beautiful images of fluorescently
tagged blood cells circulating. The imaging provides an
unbelievable amount of information about biology. To see GFP-
positive blood cells in circulation was amazing. 
In the late 2000s, chemical biology screens took off. I think you
could easily argue that zebrafish is the best chemical system. Access
to the embryos is so easy, and the field really blossomed with
interesting screens into all sorts of phenotypes. Now I think we are
at the beginning of another huge revolution with CRISPR
technology. Using this technology, my lab was able to make a
mutant in just 2 months – it was incredible. With a lot of groups
interested in disease combined with powerful genetics, we’re
inevitably going to see a growth in zebrafish disease models. In fact,
a group of zebrafish researchers (Liz Patton, Jim Amatruda, Jill
DeJong and I) recently launched the Zebrafish Disease Models
Society and we see this as an increasingly important part of the
zebrafish community.
“I think you could easily argue that
zebrafish is the best chemical system.
Access to the embryos is so easy, and
the field really blossomed with
interesting screens into all sorts of
phenotypes”
You’ve mentioned that you started as a developmental
biologist and you have walked forward from this looking at
the links between blood, stem cells and disease. Where do
you think this can go in terms of therapeutics?
I think the zebrafish works very nicely as a translational model. So
far, we have had two success stories of clinical translation – from
the tank to the bedside. In the first, we found a small molecule that
can amplify blood stem cells in a zebrafish embryo. Being a
hematologist, I knew immediately what to do with this. I presented
the finding at Dana-Farber, where I had trained and still had
contacts, and it was taken rather seriously. We were given the
opportunity to work with the Center for Human Cell Therapy, which
is geared to take basic discoveries and use them to develop standard
operating procedures that could be put into the clinic. By this time,
we had been able to show that the prostaglandin chemical we’d
identified could be added to blood stem cells in a mouse and could
amplify the number about fourfold. We recognized that the clinical
situation that it was needed for was in patients who were getting a
cord blood transplant to treat leukemia. They benefit from the cord
blood transplant after chemotherapy because it reconstitutes their
immune system, but a single cord blood transplant only allows an
engraftment of about 60% of the patients. So, the standard of care
now is to get cord bloods from two different donors. As these cord
bloods have different genetic origins, they end up ‘fighting’ each
other and eventually one of the cord bloods ‘wins’. The
immunological fight that happens isn’t a pretty one and it would be
better to avoid it by amplifying stem cells in cord blood from one
source. To test this, we took human cord blood samples, split them
and treated half with our small molecule (the other half were
untreated), before putting them into immunodeficient mice. We
showed that more mice ended up with human blood if pre-treated
with the chemical. We then set up a clinical trial involving 12
leukemia patients who were given high-dose chemotherapy. They
were going to be given the ‘standard of care’, which involves two
cord bloods, but we pre-treated one of the cord bloods for 2 hours
with our chemical and then gave both to the patient. In ten out of 12
patients, the treated cord was the one that preferentially engrafted,
and the neutrophils and platelets came back earlier after these
transplants than in control patients who had not been treated with
PGE2. This has gone from a Phase I trial now into Phase II, where
we will treat about 50 patients. 
The second story is relevant to melanoma. The melanocytes of
your skin are derived from the neural crest. Neural crest cells also
make other tissues, like the Schwann cells or cartilage. We wanted
to find a melanoma drug and we thought about antagonizing the
neural crest. We screened in embryos for a chemical that could erase
the neural crest and, out of 3000 small molecules, only one did this.
This was a novel chemical but we were able to use a
chemoinformatics database to find out that it inhibits an enzyme
called DHODH, which catalyzes a step in pyrimidine biosynthesis.
There is a drug on the market, used to treat rheumatoid arthritis, that
also targets this particular enzyme, and we were able to show that
this other chemical, leflunomide, causes the same phenotype in our
screen. In a series of experiments, we showed that leflunomide
blocks the transcription of neural crest genes and also some
proliferation genes. We then showed in human tumor xenografts in
mice that leflunomide is effective as an anti-melanoma drug, and
confirmed that leflunomide pauses transcription of neural crest and
proliferative genes in human melanomas. We’ve now treated three
patients in a clinical trial with leflunomide (together with a BRAF
inhibitor that also attacks cell proliferation) and we’re hoping to treat
43 patients in the next phase. 
An important thing that these experiences have taught me is that
it’s possible to put fish into a drug discovery pipeline but you’re
going to need multiple model organisms to actually be able to
translate. It’s pretty hard to go straight from the fish into humans so
we had to rely on intermediate steps involving mice. This is likely
to be a paradigm for how to translate work from the zebrafish. 
“An important thing that these
experiences have taught me is that it’s
possible to put fish into a drug
discovery pipeline but you’re going to
need multiple model organisms to
actually be able to translate”
If you were to give advice to us non-physician basic
researchers, what would it be?
I hope that as people do their basic research they can try to project
it somehow to the clinic. I feel that when I’m mentoring people at
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Harvard Stem Cell Institute for instance, sometimes there’s a desire
to publish basic discoveries and never get to the translation part of
it. I’ve been trying to show them there is a way to get your basic
research to the clinic. 
If you do have the desire to translate your work, then early
mentoring is absolutely critical. It’s best to get in touch with a
physician-scientist or medical doctor. I think it’s a good idea to
present your ideas to a doctor and get their feedback. Sometimes
you might have a basic discovery and you think that you’re moving
in the right direction, but somebody who is taking care of patients
might realize it’s impractical and there’s a better alternative. I will
often say “go and present your work on clinical rounds”. You have
to be thick-skinned but it can be very revealing. Meeting patients is
also rewarding. We are starting to do that with PhD students through
the Leder Human Biology and Translational Medicine program
at Harvard Medical School. 
If I were a young scientist thinking about using zebrafish to
study disease, I guess you would recommend it? What
needs to improve to make the model even more useful?
There are a couple of things I’m hoping for. A lot of people have
started working on adult zebrafish. We now have adult fish that are
transparent, like the embryos, and this opens up a lot of opportunities;
for example, in my own lab we’re doing marrow transplants in adults.
However, what we don’t have is a good way of characterizing adult
physiology. Every assay that exists in a human can be applied in some
way to the fish, but not much has been done. A major limitation is that
we lack antibodies, which would speed things up and allow the field
of adult biology to grow – I’d like to see more reagents and antibodies
be developed to allow this. 
I would also like the infrastructure of zebrafish research to be
built up a little bit better than it is. For instance, the FlyBase is
amazing and the Drosophila stock centers are well-developed. For
fish, we have two wonderful stock centers that function well, but we
don’t have much of an infrastructure to distribute and characterize
the strains. The NIH and other funding organizations could help
with this. 
Another thing that I feel is lacking is a voice or influence to push
the field forward, although this has improved since the early days.
Most people worry about their own research questions and
laboratories, and nobody has really pushed the buttons that need to be
pushed to give zebrafish research a more public face. It was similar
in the stem cell field, until investigators including myself stepped
forward to gain more support from different bodies, governments and
the public. There are lots of great meetings and great science in the
zebrafish world, but I don’t think the field is reaching its potential.
Funding is low in general, and I feel that now we’re doing so many
fantastic things – modeling disease and coming up with new therapies
– we need to start blowing our horn more to catch the attention of
funding bodies. This is why I think the Zebrafish Disease Models
Society we’ve started will be important. 
You have a physician hat, a researcher hat, and you’ve also
collaborated with pharmaceutical companies. How useful
have you found your interactions with companies?
I would encourage anybody who is starting out their lab to start
thinking about interacting with companies as early as possible.
When I initially started my lab, we were awarded a grant by
Hoffmann La-Roche, which meant we could take yearly trips to
them to learn more about how pharmaceutical companies do their
work. It was really eye-opening, particularly in terms of the scale of
the operation, to see how pharma does basic science. Some of the
people who I befriended there ended up working at Novartis, and
they asked me to be on the functional genomics board for Novartis.
Their meetings were incredibly intense, and gave me an insight into
what decisions and processes a major pharma company has to go
through. When I become a PI, I took on a consultant role for several
start-up companies. Being on the scientific advisory board of these
companies, I could really see how they matured and what
determined success or failure. 
“I would encourage anybody who is
starting out their lab to start thinking
about interacting with companies as
early as possible”
In 2007 or so, a group of my friends on the west coast were
approached by venture capitalists to start a company. They had
interesting intellectual property associated with their laboratories but
they wanted to have some input from physician-scientists. I was
brought in as one such person, as well as David Scadden
[Massachusetts General Hospital], and we became the founders of
a new company called Fate Therapeutics. Having been on the
scientific advisory boards of companies I knew a fair amount about
the process, but being a founder is fundamentally different. It was
interesting to see how the intellectual property transfers to a
company and how patents are processed. The interactions with the
company were extremely useful, and in fact I think these were
absolutely critical to the success of my lab’s prostaglandin project
for amplifying stem cells. The company, which has about 45
employees, went public at the end of 2013 and seems to be doing
well. Together with a friend, I’ve just started another company,
which is called Scholar Rock. 
There’s a rich biology on how to produce a drug on the basis of a
basic research finding, and it’s really great for scientists to learn
about this. Interacting with companies can be very fruitful.
If you hadn’t gone for science, what career path might you
have taken?
I would have been a professional trumpet player. I played in high
school and I was part of an intercollegiate band and orchestra while
in college. I have played for 32 years in the same symphony
orchestra here at Harvard. I really enjoy playing the trumpet and I
come from a musical family – my brother was a child prodigy on
the piano, and now studies music at Durham University in England. 
DMM greatly appreciates Len’s willingness to share his unique thoughts and
experiences. He was interviewed by Ross Cagan, DMM Editor-in-Chief. This piece
has been edited and condensed by Paraminder Dhillon with approval from the
interviewee.
This article is part of a Special Issue, Spotlight on Zebrafish: Translational Impact.
See all the articles in the issue at http://dmm.biologists.org/content/7/7.toc.
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